SYGNAL is the first cardiac amyloidosis screening technique
SYGNAL Solutions' screening technology for Cardiac ATTR Amyloidosis is a high-complexity algorithm that has been patented (patent is pending). The algorithm has been developed by a team of experienced medical professionals and industry experts, including renowned cardiologists. The team also includes experts in AI and algorithms development, clinical research and innovations, and cardiac electrophysiology.
SYGNAL technology is a cloud-based algorithm that can be used with existing ECG devices and novel smart devices, offering a simple, affordable, and widely available screening solution for Cardiac ATTR Amyloidosis. This groundbreaking technology has undergone two clinical trials, with promising results. The algorithm has been shown to have over 85% sensitivity and 89% specificity, making it a highly accurate tool for screening patients for this condition.
The clinical pathway includes three simple steps: first, patients with shortness of breath above the age of 65 undergo a Sygnal screening; second, identified patients undergo confirmatory analysis using SCENT, MRT, or biopsy; and finally, confirmed patients undergo treatment. Sygnal's pathway offers a comprehensive solution for patients with Cardiac ATTR Amyloidosis, addressing the high unmet need for an easy-to-use, low-cost screening solution.
CARDIAC AMYLOIDOSIS WITH
HIGH UNMET NEED
CURRENTLY ONLY 10% OF PATIENTS DIAGNOSED
Cardiac amyloidosis is a rare disease where abnormal proteins deposit in the heart, causing heart failure. With high unmet need, sadly only 10% of cases are diagnosed, leading to delayed treatment and poor outcomes. Early diagnosis is crucial, and our research aims to improve detection and develop effective therapies for this condition.
REASONS
- NO cardiac amyloidosis screening available due to lack of sensitivity & specificity
- Current diagnostic tools lack ease-of-use and availability … and are expensive
- First treatment options launched & some pipeline candidates are expected… 300k€ cost p.a.
OUR ASPIRATION FLIP-THE-RATIO … BY A SYSTEMATIC AMD SCREENING
It refers to the goal of reducing the incidence of advanced age-related macular degeneration (AMD) through regular and thorough screening programs. The term "flip-the-ratio" suggests that fewer people will develop advanced AMD and outcomes will improve. This effort underscores the importance of early detection and treatment of this disease
3m patients with cardiac amyloidosis
SYGNAL MATCHES ALL REQUIREMENTS
OF ATTR AMYLOIDOSIS SCREENING
SYGNAL - the innovative screening tool, matches all the requirements for effective detection of cardiac ATTR amyloidosis. Our technology aims to improve early diagnosis to manage this condition for improved patient outcomes.
EASE-TO-USE
Our technology is user-friendly and easy to use, making it instantly accessible for healthcare providers
85% SENSITIVITY
89% SPECIFICITY
SYGNAL Technology offers high sensitivity (85%) and specificity (89%) for accurate disease detection.
REPRODUCIBILITY
SYGNAL Technology's ATTR Amyloidosis detection has high reproducibility, ensuring reliable and accurate results every time.
NO INTERVENTION
NO RADIATION
SYGNAL technology allows for non-invasive monitoring with no intervention or radiation exposure.
LOW COST
SYGNAL technology provides cost-effective detection of ATTR amyloidosis
BROADLY AVAILABLE
By integrating the algorhytmen in existing ECG devices SYGNAL Technology can be made broadly available
© Copyright.
All rights reserved
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.